Breast cancer

Research into community pharmacists’ role in treating breast cancer funded

How community pharmacists could play a greater role in treating breast cancer is one of five research projects awarded funding by Pharmacy Research UK…

Too many cancer drugs, too few survival benefits

balke…

Safety of vaginal oestrogen in hormone replacement therapy

Vaginal oestrogen not linked to invasive breast cancer or pulmonary embolism risk.…

Medication non-adherence in breast cancer prevention and treatment

Balkees Abderrahman highlights the problem of medication non-adherence in the treatment and prevention of breast cancer.…

Statins could protect against breast cancer

Being diagnosed with hyperlipidaemia could protect you against breast cancer and early mortality, according to research presented at the European Society of Cardiology Congress 2017.…

FDA approves drug to reduce risk of HER2-positive breast cancer returning

The US Food and Drug Administration (FDA) has approved neratinib (Nerlynx; Puma Biotechnology) as the first extended adjuvant therapy for early-stage, HER2-positive breast cancer.…

Breast cancer drug Kadcyla to be routinely available in Wales

Breast cancer treatment Kadcyla (trastuzumab emtansine) will now be available routinely on the NHS in Wales after Roche, the drug’s manufacturer, agreed the same commercial access deal with NHS Wales as was recently agreed with NHS England.…

Kadcyla to get routine NHS funding after deal with Roche

Final draft guidance from the National Institute of Health and Care Excellence (NICE) recommends Kadcyla for routine use in advanced breast cancer after manufacturer Roche agreed to reduce the cost of the drug to the NHS.…

Contraceptive pill does not increase long-term cancer risk

Most women who take the contraceptive pill are not at increased risk of cancer overall and may actually gain some protection against certain cancers, researchers say.…

Breast cancer drug deemed too expensive in England has been approved in Scotland

NHS Scotland has approved the use of breast cancer drug Kadcyla, which was rejected for use in England on the grounds that its benefits did not justify its cost.…